Skip to main content

Table 1 Transmission of dCJD or sCJD to PrP-humanized mice

From: Distinct origins of dura mater graft-associated Creutzfeldt-Jakob disease: past and future problems

Inoculum (ID) Incubation period in days ± SEM ( n/n 0)a
  129 M/M 129 V/V
  Tg + Ki-Hu129 M/Mb Ki-Hu129M/Mb Ki-Hu129V/Vb
  (9.8×)c (1×) (1×)
np-dCJD (GF) 161 ± 5 (5/5) N.D. d N.D.
np-dCJD (TC) 208 ± 2 (5/5) N.D. N.D.
p-dCJD (KR) 420 ± 10 (5/5) 685 ± 51 (5/5) 259 ± 6 (6/6)
p-dCJD (KD) 398 ± 10 (5/5) 447 ± 51 (6/6) 317 ± 8 (11/11)
sCJD-MM1 175 ± 4 (9/9) 467 ± 24 (8/8) 774 ± 32 (6/6)
sCJD-VV2 505 ± 14 (5/5) 633 ± 49 (6/6) 302 ± 9 (7/7)
sCJD-MV2K N.D. 638 ± 57 (4/4) 329 ± 3 (4/4)
sCJD-MV2K+C N.D. 600 ± 22 (6/6) 332 ± 15 (4/4)
129 M/M mouse-passaged sCJD-VV2 N.D. 685 ± 17 (6/6) 309 ± 3 (7/7)
  1. a n, number of mice positive for PrP accumulation in the immunohistochemical analysis; n 0, number of inoculated mice.
  2. Ki-Hu129M/M, knock-in mice expressing human PrP with the 129 M/M genotype; Ki-Hu129V/V, knock-in mice expressing human PrP with the 129 V/V genotype; Tg + Ki-Hu129M/M, Ki-Hu129M/M crossed with transgenic mice overexpressing human PrP with the 129 M genotype.
  3. dN.D., not done.